Pharmawizard (PW) - www.pharmawizard.com - was conceived as a mobile reference guide for the informed use of medications, helping citizens to increase their knowledge about healthcare and to save money and time when purchasing drugs and in general any medication sold in a pharmacy. Pharmawizardis an innovative mobile service in the Healthcare and Pharmaceutical sector which supports: • Citizens in the “intelligent” search, comparison, purchase and ”smart” management of medicines; • Players in the healthcare market (pharmacies, physicians, hospitals, public health services, distributors and pharmaceutical producers) to better understand their patients and better promote their products. The project aim is to help the interaction of citizens and healthcare businesses with public administrations services, information and open data, through mobile technologies introducing at the best time, given the emerging new dynamics of change and opportunities, a unique and innovative mobile solution with a considerable novelty in the Health and Pharma ecosystem. The project’s focus is on the fostering and facilitating interactions between citizens and healthcare companies with government-operated healthcare systems (specifically services and official data and open data related to drugs, pharmacies, biomedicals and any consumer health product). Pharmawizard provides official (public) data and open data in cooperation with the Ministries, National and European medicine Agencies, in a simple and flexible way, for free, and its business model is in creating value-added services, using data for citizens and, consequently, for companies in the healthcare industry. PW vision is that data must be provided to everyone for free (open data, data normalization, etc.); and we strongly believe that a successful initiative in the digital world is the one who will be able to build a set of value added services upon these data.

With an increasingly growing population in Europe, cognitive impairments as well as heart diseases are a major social and health issue. 1.2 million people in Europe are affected by Parkinson's disease (PD) while Alzheimer’s disease remains one of the biggest global public health challenges our generation is facing, while Cardiovascular disease represented the 31% of all global deaths in 2016. Based on these facts, the affecTive basEd iNtegrateD carE for betteR Quality of Life TeNDER project will create an integrated care ecosystem for assisting people with chronic diseases of Alzheimer’s (AD), Parkinson’s (PD) and comorbidity with Cardiovascular Diseases (CVD) through the use of affect based micro tools. These microservices will recognise the mood of a person and thus adapt the system’s probes to the person’s needs via a multi-sensorial system, even in the most severe cases, and match with clinical (from Electronic Health Records EHRs) and clerical patient information, while preserving privacy, monitoring the ethical principles, providing data protection and security, with the result of an increased Quality of Life (QoL). In addition, interactive communication and social services will strength the elderly support, extending their autonomy and care supply chain. TeNDER will perform 5 large scale pilots, involving 5 user partners and 1500+ TeNDER final users in 4 different European regions, with at least 735 patients (+40% in the patients control group, making a total of 1030 patients), 85 health professionals (physicians mainly), 30 social workers, 570 caregivers (professional and relatives) and 60 other staff (clerks, Hospital IT support, etc.), to provide tailor suited integrated care services to promote wellbeing and health recovery. TeNDER will provide 4 different scenarios according to the patients pathways (home, daycare centre, rehabilitation centre/rooms, and hospital).

Haematological diseases (HDs) are a large group of disorders resulting from quantitative or qualitative abnormalities of blood cells, lymphoid organs and coagulation factors. Despite most of them (~74%) are rare, the overall number of HD affected patients worldwide is important, placing a considerable economic burden on healthcare systems and societies. Despite the existence of several collaborative research groups at national and EU level, current clinical approaches are often ineffective, particularly for rarest conditions, due to the relatively low number of patients per disease and the high number of unconnected clinical entities. SYNTHEMA aims to establish a cross-border data hub where to develop and validate innovative AI-based techniques for clinical data anonymisation and synthetic data generation (SDG), to tackle the scarcity and fragmentation of data and widen the basis for GDPR-compliant research in RHDs. The project will focus on two representative RHD use cases: sickle-cell disease (SCD) and acute myeloid leukaemia (AML). SYNTHEMA will develop a federated learning (FL) infrastructure, equipped with secure multiparty computation (SMPC) and differential privacy (DF) protocols, connecting clinical centres bringing standardised, interoperable multimodal datasets and computing centres from academia and SME. This framework will be utilised to train the developed algorithms and perform SMPC-based global model aggregation in a privacy-preserving fashion. The resulting data will be validated for their clinical value, statistical utility and residual privacy risks. The project will develop legal and ethical frameworks to guarantee privacy by-design in the collection and processing of health-related personal data and attain an ethics-wise algorithm co-creation. Project outcomes, including pipelines, standards and data, will be made openly available to stakeholders in the healthcare, academia and industry field, and contribute to existing rare disease registries

Proper nutrition is essential for good health, well-being and the prevention, mitigation or treatment of a number of non-communicable diseases (NCDs). Food is not only a source of calories, but also a complex mixture of dietary chemicals, some of which are directly related to cardiovascular diseases, diabetes, allergies and some types of cancer. Foods, diet and nutritional status, including overweight and obesity, are also associated with elevated blood pressure and blood cholesterol or even resistance to the action of insulin. These conditions are not only risk factors for non-communicable diseases, but major causes of illness themselves. However, today's diet is characterized by irregular and poorly balanced meals. Unhealthy eating habits in our daily life are not only risk factors for non-communicable diseases, but also major causes of stress and tiredness, i.e., lack of energy. Knowledge about our dietary habits based on the analysis of diverse types of information, including individual parameters, can contribute greatly towards answering key questions to respond to societal challenges regarding food and health. Motivated by the aforementioned, the PROTEIN project aims to develop an end-to-end ecosystem that will engage people to a healthy, pleasurable, nutritional and sustainable diet by offering a daily program adapted to their needs and driven by their personal preferences, physical and physiological characteristics as well as their health status. Specifically, the main objective of PROTEIN is to create an ICT-based system for providing personalized nutrition based on the collection and analysis of large volumes of data related to users' dietary behavioural patterns, physical activity and individual parameters. PROTEIN proposes a radically novel approach to advice and support consumers in everyday living, while ensuring users’ privacy protection i.e., data will be anonymized and securely stored in the Cloud for processing.

Thera4Care represents a large unique consortium, gathering well-established European academic radiotheranostic centres, strong industry partners, European and medical societies focusing on training and education, a patient advocacy group spearheaded by an experienced project management group. Thera4Care aims to establish a European network of radiotheranostics centres able to rapidly develop and implement radiotheranostics tools and solutions to drive precision health. The overarching vision of Thera4Care is to revolutionise radiotheranostics procedures by establishing, implementing, and disseminating standardised scalable methods to produce and efficiently administer key radiotheranostics solutions. Thera4Care focus is on developing diagnostic and therapeutic ligands tailored to key disease areas (such as solid tumours), aligning with the growing significance of multi-modal radiotheranostics solutions dominated by radionuclide-based therapy and companion diagnostics. Thera4Care project is scheduled for 5 years and consists of 9 work packages. WP1 handles Project Management, WP2 focuses on Regulatory aspects, WP3 plans Preclinical studies, WP4 provides Supply chain, WP5 develops Clinical Trials, WP6 generates AI models, WP7 focuses on Dosimetry, WP8 develops Precision Imaging components, while WP9 focuses on Education and Dissemination. Thera4Care will advocate for the progress of radiotheranostics, with the goal of increasing medical knowledge and enhancing treatment efficacy for improved patient outcomes. Concurrently, aims to coordinate scientific initiatives across European landscapes, leveraging a comprehensive and multimodal approach to cancer therapy applicable to various cancer types. Lastly, will work on the establishment of sustainable supply and production networks and the upscaling of production methodologies and supply chains across the public and private sectors, to enhance the availability of radionuclides.